Inhibitory effects of Endostar combined with Oxaliplatin on human colon cancer cells

OBJECTIVE:To explore the effects of combination of Endostar and Oxaliplatin on colon cancer cell growth,adhesion and migrationin vitro.METHODS:Cell counting method was conducted for the effects of Endostar combined with Oxaliplatin on the growth of HCT116and SW480cells.Tumor cell migration and adhesion were tested using Boyden Chamber and crystal violet staining.RESULTS:Cell proliferation assay showed individual Endostar(18μg/mL), Oxaliplatin(0.25μg/mL)or the combination of Endostar Oxaliplatin inhibited tumor cell growth compared with the control,with inhibitory rate at 24%,32%and 45%in HCT116cells and 20%,31%and 41%in SW480cells respectively. In addition,Endostar plus Oxaliplatin had stronger inhibitory effects on cell growth than single drug did,and the difference was statistically significant(P=0.041in HCT116cells and P=0.022in SW480cells for Endostar;P=0.033in HCT116 cells and P=0.029in SW480cells for Oxaliplatin).The inhibitory effects were time-dependent,in which the inhibitory rate reached 55%in HCT116(t=12.57,P=0.024)and 56%in SW480(t=9.798,P=0.031)after 120-hour cell culture.Endostar combined with Oxaliplatin inhibited both cell migration and adhesion in HCT116cells.Compared with control group,combination group inhibited HCT116cell migration by 86.1%(t=2.054,P=0.000 7),and cell adhesion by 55.6%(t=25.74,P=0.029)respectively.However the combined drugs did not affect SW480cell migration,but inhibited cell adhesion by 66.4%(t=12.47,P=0.012).Thus,the inhibitory effects of the combined drugs on HCT116were superior to those in SW480with respect to cell migration and cell adhesion.CONCLUSIONS:Endostar combined with Oxaliplatin showed synergistic activity on inhibiting colon cancer cell development.It shows therapeutic function for treatment of colon cancer through various steps including inhibiting cell proliferation,migration and adhesion.Our in vitro results provide theoretical rationale for colon cancer treatment using Endostar plus Oxaliplatin regimen in the future.